Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: KK reports personal fees from Astra Zeneca and GSK outside the submitted work. RJ has nothing to disclose. HUK grants and personal fees from Bayer, Siemens, Boehringer Ingelheim, Philips, MSD, Sanofi and Median outside the submitted work. PA has nothing to disclose with regard to this manuscript. FCT reports personal fees from Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Grifols, Novartis outside the submitted work. FH has nothing to disclose with regard to this manuscript. BJ has nothing to disclose with regard to this manuscript. OW reports that parts of the airways analysis algorithm have been licensed to the company Imbio, LLC. SN has nothing to disclose with regard to this manuscript. PM has nothing to disclose with regard to this manuscript. DK has nothing to disclose with regard to this manuscript. JB has nothing to disclose with regard to this manuscript. RB reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, personal fees from Grifols, grants and personal fees from Novartis, personal fees from CSL Behring, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), grants from Sander Stiftung, grants from Schwiete Stiftung, grants from Krebshilfe, grants from Mukoviszidose eV, outside the submitted work. HW has nothing to disclose with regard to this manuscript. JB has nothing to disclose with regard to this manuscript. KFR reports personal fees from Astra Zeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Novartis, Sanofi & Regeneron, GlaxoSmithKline, Berlin Chemie, Roche Pharma, as well as leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for German Center for Lung Research (DZL), German Chest Society (DGP), American Thoracic Society (ATS) outside the submitted work. TW reports grants from German Federal Ministry of Education and Research (BMBF). CFV reports personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmed, Menarini, Novartis, Nuvaira, Novartis outside the submitted work, as well as grants for the institution from German Federal Ministry of Education and Research (BMBF) and AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Grifols and Novartis. JBi reports leadership of the ESTI (European Society of Thoracic Imaging) president 2022/2023 (unpaid) and outside the submitted work."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by the German Centre for Lung Research (DZL), grant number 82DZLI05A2 (COSYCONET), the BMBF, grant number FKZ 01GI0881, and is furthermore supported by unrestricted grants from AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, GlaxoSmithKline, Grifols Deutschland GmbH, Novartis Deutschland GmbH. The funding body was not involved in the design of the study, or the collection, analysis or interpretation of the data."

"Registration:: ClinicalTrials.gov, Identifier: NCT01245933"